703 related articles for article (PubMed ID: 29562686)
1. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
2. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Kahn B; Collazo J; Kyprianou N
Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
[TBL] [Abstract][Full Text] [Related]
6. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
Altschuler J; Stockert JA; Kyprianou N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
[TBL] [Abstract][Full Text] [Related]
7. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
8. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
Livas L; Hasani S; Kyprianou N
Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
[TBL] [Abstract][Full Text] [Related]
9. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.
Grant CM; Kyprianou N
Transl Androl Urol; 2013 Sep; 2(3):202-211. PubMed ID: 25346895
[TBL] [Abstract][Full Text] [Related]
10. Achieving resistance specificity in prostate cancer.
Wadhwa B; Dumbre R
Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
[TBL] [Abstract][Full Text] [Related]
11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
12. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.
Zhu ML; Kyprianou N
FASEB J; 2010 Mar; 24(3):769-77. PubMed ID: 19901020
[TBL] [Abstract][Full Text] [Related]
13. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
Nepali PR; Kyprianou N
Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
[TBL] [Abstract][Full Text] [Related]
14. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
Dicken H; Hensley PJ; Kyprianou N
Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
[TBL] [Abstract][Full Text] [Related]
15. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.
Cao Z; Livas T; Kyprianou N
Crit Rev Oncog; 2016; 21(3-4):155-168. PubMed ID: 27915969
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F
Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
Hendrix LN; Hamilton DA; Kyprianou N
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
[TBL] [Abstract][Full Text] [Related]
18. Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.
Cao Z; Koochekpour S; Strup SE; Kyprianou N
Oncotarget; 2017 Oct; 8(45):78507-78519. PubMed ID: 29108245
[TBL] [Abstract][Full Text] [Related]
19. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
Paller C; Pu H; Begemann DE; Wade CA; Hensley PJ; Kyprianou N
Prostate; 2019 Jan; 79(1):31-43. PubMed ID: 30155899
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition in prostate cancer: an overview.
Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
